Glycoprotein S3Alternative Names: gp S3
Latest Information Update: 25 Jun 1998
At a glance
- Originator Kureha Corporation
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Jun 1998 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 03 Jul 1997 New profile
- 03 Jul 1997 Preclinical development for Cancer in Japan (Unknown route)